Lastly, a phase III trial led by the European Organization for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute investigated adjuvant 5-flurouracil, INF-α, and IL-2 vs. observation in high-risk RCC patients after CRN [15]. This evidence concerns the gene IFNA17 and renal cell adenocarcinoma.